The Matrix Metalloproteinase Inhibitor Prinomastat Enhances Photodynamic Therapy Responsiveness in a Mouse Tumor Model

Cancer Research

Volumn 64, Issue 7, 2004, Pages 2328-2332

  Ferrario, Angela ^a   Chantrain, Christophe F ^a,b   Von Tiehl, Karl ^a   Buckley, Sue ^a   Rucker, Natalie ^a   Shalinsky, David R ^c   Shimada, Hiroyuki ^a   DeClerck, Yves A ^a,b   Gomer, Charles J ^a,b,c,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c AGOURON PHARMACEUTICALS INC   (United States)

^d CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PHOTOFRIN; PRINOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARGON LASER; ARTICLE; BLOOD VESSEL INJURY; BREAST TUMOR; CANCER MODEL; CELL DEATH; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME ACTIVITY; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR RECURRENCE; ZYMOGRAPHY;

ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DIHEMATOPORPHYRIN ETHER; DRUG SYNERGISM; HUMANS; ISOENZYMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASES; MICE; ORGANIC CHEMICALS; PHOTOCHEMOTHERAPY;

EID: 1942538556     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0071     Document Type: Article

References (25)

1. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst. (Bethesda) 1998;90:889-905.
2. Schmidt-Erfurth U, Miller JW, Sickenberg M. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a Phase 1 and 2 study. Arch Ophthalmol 1999;117:1177-8.
3. Gollnick SO, Evans SS, Baumann H, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 2003;88:1772-9.
4. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ. Anti-angiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000;60:4066-9.
5. Ferrario A, von Tiehl KF, Wong S, Luna M, Gomer CJ. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res 2002;62:3956-61.
6. Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents [Review]. Adv Cancer Res 2000;79:1-38.
7. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
8. Bergers G, Coussens LM. Extrinsic regulators of epithelial tumor progression: metalloproteinases. Curr Opin Genet Dev 2000;10:120-7.
9. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
10. Scharffetter-Kochanek K, Wlaschek M, Briviba K, Sies H. Singlet oxygen induces collagenase expression in human skin fibroblasts. FEBS Lett 1993;331:304-6.
11. Chantrain CF, Shimada H, Groshen S, et al. Stromal matrix metalloproteinase-9 (MMP-9) regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res 2004;64:1675-86.
12. Bremer C, Tung, C-H, Weissleder R. In-vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001;7:743-8.
13. Verheijen JH, Nieuwenbroek NME, Beekman B, et al. Modified proenzymes as artificial substrates for proteolytic enzymes: colorimetric assay of bacterial collagenases and matrix metalloproteinases activity using modified pro-urokinase. Biochem J 1997;323:603-9.
14. Schmalfeldt B, Prechtel D, Harting K, et al. Increased expression of matrix metalloproteinases MMP-2, MMP-9 and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian carcinoma. Clin Cancer Res 2001;7:2396-404.
15. Sienel W, Hellers J, Morresi-Hauf A, et al. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 2003;103:647-51.
16. Rudd PM, Mattu S, Masure S, et al. Glycosilation of natural human neutrophil gelatinase B and neutrophil gelatinase B-associated lipocalin. Biochemistry 1999;38:13937-50.
17. Shibata K, Kikkawa F, Nawa A, Tamakoshi K, Suganuma N, Tomoda Y. Increased matrix metalloproteinase-9 activity in human ovarian cancer cells cultured with conditioned medium from peritoneal tissue. Clin Exp Metastasis 1997;15:612-9.
18. Foda HD, Rollo EE, Drews M, et al. Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN. A. J Respir Cell Mol Biol 2001;25:717-24.
19. Guo H, Zucker S, Gordon MK, Toole BP, Biswas C. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem 1997;272:24-7.
20. Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin. Exp Metastasis 2003;20:161-9.
21. Wojtowicz-Praga S. Clinical potential of matrix metalloprotease inhibitors. Drugs Res Dev 1999;1:117-29.
22. Nuttall RK, Kennedy TG. Gelatinase A and B and the tissue inhibitors of metalloproteinases 1, 2, and 3 during in-vivo and in-vitro decidualization of rat endometrial stromal cells. Biol Reprod 1999;60:471-8.
23. Takahashi S, Inoue T, Higaki M, Mizushima Y. Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinases 1 (proMMP-1) in human rheumatoid synovial fibroblasts. Inflammation Res 1997;46:320-3.
24. Coussens LM, Fingleton B, Matrisan LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (Wash DC) 2002;295:2387-92.
25. Shalinsky DR, Brekken J, Zou H, et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann N Y Acad Sci 1999;878:236-70.